Intimation of Allotment of 8250 Equity shares under Rossari Employee Stock Option Plan-2019.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech's board approved audited results for Q4 and FY26. Consolidated revenue from operations rose to Rs. 23,963.65 million (vs Rs. 20,802.94 million in FY25), and profit after tax grew to Rs. 1,492.13 million (vs Rs. 1,363.78 million), with basic EPS of Rs. 26.95. The board recommended a final dividend of Re. 0.50 per share (25%) for FY25-26, subject to shareholder approval. It allotted 8,250 equity shares under the ESOP 2019 at an exercise price of Rs. 425 each, taking total paid-up equity to Rs. 11.08 crore (5,53,91,616 shares). A new R&D facility was set up in Navi Mumbai, replacing the older one at IIT Bombay. The company also said its previously announced capacity expansion project is being rescheduled and will now be executed in a phased manner over the next two years, though strategic intent remains unchanged.
Strong topline and profit growth with a modest dividend support the stock, while the two-year phased delay in the capacity expansion could temper near-term capex/expansion expectations. The new R&D facility and seasoned independent director add long-term capability and governance strength.